VICL

AcronymDefinition
VICLVirgin Islands Charteryacht League
VICLVancouver Island Coach Lines (Canada)
References in periodicals archive ?
The updated VICL line, featuring a unique, patent-pending skin protection complex, will contain special ingredients that are said to work in synergy to provide moisturization and significant protection against the environmental factors that cause dry skin--sun, wind, water and cold.
To make individual selection easier for the consumer, the VICL line has been tailored from seven variants to four.
The reformulated VICL products have a contemporary and easily identifiable look-prominently featuring primary benefits and key ingredients on the front panel.
Tickers featured: ABGX, ALKS, AMGN, AZN, BGEN, BMY, CVTX, DNA, ENZN, GILD, GNVC, IDPH, ILXO, IMCLE, ISIS, JNJ, LJPC, MEDI, MLNM, NBIX, NPS, NPSP, NVS, OSIP, PFE, SCIO, SRA, TGEN, VICL, VRTX.
Tickers featured: ABGX, ABT, ALLP, AMGN, AMLN, AVE, AVGN, BGEN, BMY, CEGE, CRA, DNA, DOW, DVSA, FBR, GILD, GNVC, HGSI, IDBE, IDPH, IMCL, IMNX, ISIS, JNJ, KERX, LLY, MEDI, MLNM, NWBT, ONXX, SCLN, SRA, SYT, TELK, TRMS, TTP, VICL. Complete text approximately 15-20,000 words.
15 July 2011 - US Vical Incorporated (NASDAQ: VICL) and Japanese Astellas Pharma Inc (TYO: 4503) said yesterday they have sealed exclusive licence agreements for the US and for all territories in the rest of world outside the US to develop and commercialise TransVax, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
28 April 2011 - US-based biopharmaceutical company Vical Incorporated (NASDAQ: VICL) announced yesterday that more than half of the subjects in the Phase I trial of the company's Vaxfectin-formulated vaccine for H1N1 pandemic influenza generated neutralising antibodies of the type expected to provide protection against the disease.
10 November 2010 - US-based biopharmaceutical company Vical Incorporated (NASDAQ: VICL) said yesterday that it booked a net loss of USD6.8m (EUR4.9m), or USD0.12 per share, for the third quarter of 2010, compared with a net loss of USD7.0m, or USD0.14 per share, for the third quarter of 2009.
7 October 2010 - US Vical Incorporated (NASDAQ: VICL) said on Thursday it has agreed to manufacture plasmid DNA (pDNA) vaccines against HIV under a USD2.4m (EUR1.7m) deal with the IPPOX Foundation, a collaborating institution for the Poxvirus Vaccine Regimen Design (PVRD) led by the Centre Hospitalier Universitaire Vaudois (CHUV) under the auspices of the Collaboration for AIDS Vaccine Discovery (CAVD).
29 January 2010 - US biopharmaceutical products maker Vical Incorporated (NASDAQ: VICL) said yesterday it has completed enrollment of the planned 375 subjects in its Phase III trial of Allovectin-7 in patients with metastatic melanoma.
14 January 2010 - US biopharmaceutical products maker Vical Incorporated (NASDAQ: VICL) said today it has named Richard Kenney vice president, Clinical Development.
28 December 2009 - US-based biopharmaceutical products developer Vical Incorporated (NASDAQ: VICL) said today that an independent Safety Monitoring Board (SMB) for its Phase III AIMM trial of Allovectin-7 in patients with metastatic melanoma has completed the trial's third scheduled safety analysis and recommended that the study continue per the protocol.